ELTROMBOPAG: 5,473 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
5,473
Total FAERS Reports
1,434 (26.2%)
Deaths Reported
2,066
Hospitalizations
5,473
As Primary/Secondary Suspect
432
Life-Threatening
96
Disabilities
None
Status
FDA Application: 208815 ·
First Report: 199901 · Latest Report: 20250924
What Are the Most Common ELTROMBOPAG Side Effects?
#1 Most Reported
Platelet count decreased
968 reports (17.7%)
#2 Most Reported
Death
629 reports (11.5%)
#3 Most Reported
Drug ineffective
554 reports (10.1%)
All ELTROMBOPAG Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Platelet count decreased | 968 | 17.7% | 148 | 545 |
| Death | 629 | 11.5% | 629 | 80 |
| Drug ineffective | 554 | 10.1% | 86 | 201 |
| Product use in unapproved indication | 303 | 5.5% | 70 | 69 |
| Thrombocytopenia | 262 | 4.8% | 33 | 112 |
| Off label use | 255 | 4.7% | 50 | 87 |
| Headache | 229 | 4.2% | 27 | 125 |
| Pyrexia | 229 | 4.2% | 45 | 163 |
| Haemoglobin decreased | 213 | 3.9% | 41 | 117 |
| Pneumonia | 204 | 3.7% | 86 | 124 |
| Platelet count increased | 186 | 3.4% | 24 | 101 |
| Haemorrhage | 173 | 3.2% | 35 | 80 |
| Therapy non-responder | 166 | 3.0% | 39 | 42 |
| Malaise | 154 | 2.8% | 31 | 116 |
| Anaemia | 146 | 2.7% | 28 | 53 |
| Sepsis | 143 | 2.6% | 100 | 65 |
| Fatigue | 142 | 2.6% | 20 | 65 |
| Pulmonary embolism | 138 | 2.5% | 22 | 89 |
| Diarrhoea | 135 | 2.5% | 21 | 72 |
| Aplastic anaemia | 131 | 2.4% | 56 | 45 |
Who Reports ELTROMBOPAG Side Effects? Age & Gender Data
Gender: 53.5% female, 46.5% male. Average age: 55.3 years. Most reports from: JP. View detailed demographics →
Is ELTROMBOPAG Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 1 | 1 | 0 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 1 |
| 2010 | 8 | 2 | 3 |
| 2011 | 61 | 19 | 24 |
| 2012 | 65 | 8 | 36 |
| 2013 | 95 | 19 | 49 |
| 2014 | 187 | 40 | 127 |
| 2015 | 362 | 73 | 232 |
| 2016 | 249 | 54 | 150 |
| 2017 | 308 | 94 | 160 |
| 2018 | 436 | 131 | 185 |
| 2019 | 426 | 159 | 192 |
| 2020 | 329 | 156 | 134 |
| 2021 | 54 | 14 | 29 |
| 2022 | 33 | 4 | 15 |
| 2023 | 34 | 1 | 12 |
| 2024 | 35 | 1 | 20 |
| 2025 | 16 | 1 | 12 |
What Is ELTROMBOPAG Used For?
| Indication | Reports |
|---|---|
| Immune thrombocytopenic purpura | 1,734 |
| Aplastic anaemia | 1,121 |
| Immune thrombocytopenia | 792 |
| Product used for unknown indication | 612 |
| Thrombocytopenia | 531 |
| Myelodysplastic syndrome | 246 |
| Thrombocytopenic purpura | 117 |
| Platelet count decreased | 57 |
| Bone marrow failure | 52 |
| Acute myeloid leukaemia | 40 |
ELTROMBOPAG vs Alternatives: Which Is Safer?
ELTROMBOPAG vs ELTROMBOPAG OLAMINE
ELTROMBOPAG vs ELUXADOLINE
ELTROMBOPAG vs ELVITEGRAVIR
ELTROMBOPAG vs EMAPALUMAB
ELTROMBOPAG vs EMAPALUMAB-LZSG
ELTROMBOPAG vs EMEND
ELTROMBOPAG vs EMICIZUMAB
ELTROMBOPAG vs EMICIZUMAB-KXWH
ELTROMBOPAG vs EMPAGLIFLOZIN
ELTROMBOPAG vs EMPAGLIFLOZIN\LINAGLIPTIN
Official FDA Label for ELTROMBOPAG
Official prescribing information from the FDA-approved drug label.